news
EMA recommendations on compassionate use of remdesivir for COVID-19
The European Medicines Agency has released recommendations about which patients could benefit from remdesivir and the possible criteria for compassionate use of the drug.
List view / Grid view
Drug Markets
news
Influenza antiviral Avigan® (favipiravir) to enter Phase III trials in COVID-19 patients
The developers of Avigan have increased production and announced a Phase III clinical trial testing its efficacy against COVID-19.
news
EMA accepts marketing authorisation application for anti-epileptic drug cenobamate
Cenobamate’s application was based on a global clinical trials programme enrolling over 1,900 adults with uncontrolled focal-onset seizures.
article
COVID-19 update: coronavirus and the pharmaceutical supply chain
With concerns rising about medicine availability during the global COVID-19 coronavirus pandemic, European Pharmaceutical Review explores how the pharmaceutical supply chain is faring.
news
Accord to donate four million tablets to global COVID-19 prophylaxis trial
The enterprise announced it will donate two million hydroxychloroquine tablets and the same of matched placebo to the multi-national COPCOV study.
news
Wearable patch device could provide an affordable insulin therapy for type 2 diabetics
A study comparing the V-Go device administering regular human insulin and rapid acting insulin analogues found they were equally effective and safe at controlling blood glucose.
news
EMA warns consumers about falsified COVID-19 drugs from online pharmacies
The European Medicines Agency (EMA) has advised consumers on how to recognise registered online pharmacies so they can avoid falsified medications.
news
Female directors are quicker to recall defective medicinal products, finds study
The presence of female directors makes boards more likely to report lower-severity defects and faster to recall products with high-severity problems, suggests research.
news
Study suggests Zolgensma will generate $2.5bn of global sales by 2025
According to researchers, Zolgensma, made by Novartis, will lead the global spinal muscular atrophy market and generate billions in sales.
news
Big pharma’s in-house manufacturing impacted by COVID-19 outbreak in China
According to an outlet, the in-house manufacturing of biopharma products has been threatened by the COVID-19 outbreak, especially in China.
news
FDA approves Zeposia® (ozanimod) to treat relapsing forms of multiple sclerosis
The US FDA has granted approval to BMS for Zeposia, a once daily oral medication for the treatment of relapsing forms of multiple sclerosis.
news
Committee for Medicinal Products for Human Use (CHMP) meeting highlights
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
news
UK government calls for increased supply of COVID-19 testing kits
The UK government has reached out to the life sciences sector to ask potential suppliers of COVID-19 testing kits to get in contact.
news
Mylan and Upjohn transaction closure delayed by COVID-19
Mylan and Upjohn (a Pfizer company) revealed they have delayed the transaction due to meeting restrictions and concerns over staff health and safety during the COVID-19 pandemic.
news
Indian government ceases exports of Ipca (hydroxychloroquine)
India has stopped exporting the malaria drug Ipca (hydroxychloroquine), despite the FDA lifting its ban on imports due to its potential as a coronavirus treatment.
